 Pathologic changes androgen deprivation therapy prostate cancer Prostate glands deprivation leuprolide flutamide pathologic changes pretreatment posttreatment tissue visual discrimination light microscopic study treatment-related alterations size distribution neoplastic glands cases Quantitative measurements glandular changes percentage cases distinctive histologic pattern specific leuprolide/flutamide absence appreciable degeneration necrosis tumor cells type androgen deprivation suppression ablation prostatic cancers relationship treatment-related histologic effects initial tumor grade clinical stage expression prostate-specific antigen Accurate histologic assessment leuprolide/flutamide-treated prostate glands problem specimens drug-related variations tumor morphologic features